Paul Campanelli is CEO at PAR PHARMACEUTICAL COMPANIES, INC. (PRX). They have made 10 open-market trades across 2 companies since 2007, most recently 2021-04-06.
CIK 0001392459
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $432K since 2007, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ENDP | BUY | 2017-08-14 | 2017-08-15 | $7.71 | $50K | +10.0% | +5.5% | -18.1% |
| ENDP | BUY | 2017-03-16 | 2017-03-16 | $10.72 | $25K | +0.4% | +0.4% | +2.0% |
| ENDP | BUY | 2016-05-10 | 2016-05-11 | $15.53 | $202K | +9.8% | +19.3% | +60.5% |
| ENDP | BUY | 2015-11-11 | 2015-11-12 | $55.69 | $117K | -11.9% | +0.1% | -14.7% |
| PRX | SELL | 2011-03-08 | 2011-03-09 | $30.73 | $1.5M | N/A | N/A | N/A |
| PRX | SELL | 2011-03-07 | 2011-03-09 | $30.76 | $3.2M | N/A | N/A | N/A |
| PRX | SELL | 2011-03-07 | 2011-03-09 | $30.90 | $466K | N/A | N/A | N/A |
| PRX | SELL | 2010-03-02 | 2010-03-03 | $25.04 | $623K | N/A | N/A | N/A |
| PRX | SELL | 2009-08-24 | 2009-08-26 | $20.25 | $632K | N/A | N/A | N/A |
| PRX | BUY | 2007-10-03 | 2007-10-03 | $18.19 | $38K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.